ERIS Lifescience Q1 FY27 Results (NSE: ERIS)
Signal: Margin expansion
The read
Q1FY27 shows revenue growth decelerating to +7.4% YoY (lowest in 8 quarters) but PAT surging +41.5% due to margin expansion and lower finance cost. OPM at 36% marks the 2nd consecutive quarter of expansion, yet the reliance on domestic branded formulations growth (only +5.2%) raises questions about Q2 seasonality. US subsidiary contributed ₹100 Cr (+25% YoY), partially offsetting domestic weakness.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹773 Cr | +7.4% | +2.1% |
| EBIT | ₹278 Cr | +9.0% | |
| Net profit | ₹125 Cr | +41.5% | |
| EPS | ₹8.66 | +41.5% | |
| EBIT margin | 36% |
P&L walk
Revenue grew 7.4% YoY to ₹773 Cr, the slowest in the prior 8 quarters; OPM expanded 100bps YoY to 36%, the 2nd consecutive quarter of margin expansion, aided by stable input costs and operating leverage. PAT surged 41.5% YoY to ₹125 Cr, outpacing operating profit growth due to lower finance cost and higher other income.
Key positives
- PAT surged 41.5% YoY to ₹125 Cr, the highest Q1 PAT in the series, driven by OPM expansion (+100bps YoY) and lower finance cost (-16% YoY).
- US subsidiary revenue grew 25% YoY to ₹100 Cr, contributing 12.9% of consolidated revenue, up from 11.1% a year ago.
- EBITDA margin at 36.2% (+40bps YoY) reflects continued margin discipline despite R&D spend increasing 25.8% YoY.
- EPS of ₹8.66 (+41.5% YoY) tracked PAT growth with no dilution, and auditor gave unmodified opinion.
Key concerns
- Revenue growth decelerated to +7.4% YoY, the slowest in at least 8 quarters, from +27.9% in Q4FY26 and +54.2% in Q1FY26.
- Domestic branded formulations growth of +5.2% YoY suggests market share pressure or seasonality; segment driver not explicitly named.
- Employee cost grew 9.4% YoY, outpacing revenue growth, indicating sticky fixed cost base.
Research and educational content only. Not investment advice.